Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia

Molecular Cancer Therapeutics

Volumn 7, Issue 4, 2008, Pages 769-778

  Chou, C James ^a   Farkas, Michelle E ^b   Tsai, Sherry M ^b   Alvarez, David ^a,c   Dervan, Peter B ^b   Gottesfeld, Joel M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b California Institute of Technology   (United States)

^c KEAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; DISTAMYCIN A; HISTONE H4; POLYAMIDE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG ELIMINATION; DRUG INHIBITION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ALKYLATION; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHLORAMBUCIL; FEMALE; HISTONES; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NYLONS; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42249094879     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0130     Document Type: Article

References (46)

1. Lee ST, Neelapu SS, Kwak LW. Therapeutic vaccine for lymphoma. Yonsei Med J 2007;48:1-10.
2. Hengstler JG, Bockamp EO, Hermes M, et al. Oncogene-blocking therapies: new insights from conditional mouse tumor models. Curr Cancer Drug Targets 2006;6:603-12.
3. Johnston SRD, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 2006;42:441-53.
4. Ren RB. Modeling the dosage effect of oncogenes in leukemogenesis. Curr Opin Hematol 2004;11:25-34.
5. O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci 2006;11:1620-35.
6. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.
7. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006;16:92-9.
8. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81.
9. Filippini C, Bisiach M, Tagliabue G, Dincalci M, Ubezio P. Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove-alkylating agents. Int J Cancer 1997;72:801-9.
10. Izbicka E, Tolcher AW. Development of novel alkylating drugs as anticancer agents. Curr Opin Investig Drugs 2004;5:587-91.
11. Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 2005;5:285-96.
12. Weiss GR, Poggesi I, Rocchetti M, et al. A phase I and pharmaco-kinetic study of tallimustine [PNU152241 (FCE 24517)] in patients with advanced cancer. Clin Cancer Res 1998;4:53-9.
13. Lockhart AC, Howard M, Hande KR, et al. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 2004;10:468-75.
14. Broggini M, Coley HM, Mongelli N, et al. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (Fce-24517), a benzoyl nitrogen-mustard derivative of distamycin. Nucleic Acids Res 1995;23:81-7.
15. Broggini M, Marchini S, Fontana E, Moneta D, Fowst C, Geroni C. Brostallicin: a new concept in minor groove DNA binder development. Anticancer Drugs 2004;15:1-6.
16. Herzig MCS, Trevino AV, Arnett B, Woynarowski JM. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry 1999;38:14045-55.
17. Dervan PB, Edelson BS. Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol 2003;13:284-99.
18. Dudouet B, Burnett R, Dickinson LA, et al. Accessibility of nuclear chromatin by DNA binding polyamides. Chem Biol 2003;10:859-67.
19. Best TP, Edelson BS, Nickols NG, Dervan PB. Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A 2003;100:12063-8.
20. Edelson BS, Best TP, Olenyuk B, et al. Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Res 2004;32:2802-18.
21. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Res 2007;35:363-70.
22. Dickinson LA, Gulizia RJ, Trauger JW, et al. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc Natl Acad Sci U S A 1998;95:12890-5.
23. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A 2004;101:16768-73.
24. Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A 2007;104:10418-23.
25. Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol 2007;2:561-71.
26. Janssen S, Cuvier O, Muller M, Laemmli UK. Specific gain- and lossof-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster. Mol Cell 2000;6:1013-24.
27. Janssen S, Durussel T, Laemmli UK. Chromatin opening of DNA satellites by targeted sequence-specific drugs. Mol Cell 2000;6:999-1011.
28. Burnett R, Melander C, Puckett JW, et al. DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA center dot TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci U S A 2006;103:11497-502.
29. Wurtz NR, Dervan PB. Sequence specific alkylation of DNA by hairpin pyrrole-imidazole polyamide conjugates. Chem Biol 2000;7:153-61.
30. Oyoshi T, Kawakami W, Narita A, Bando T, Sugiyama H. Inhibition of transcription at a coding sequence by alkylating polyamide. J Am Chem Soc 2003;125:4752-4.
31. Shinohara K, Narita A, Oyoshi T, Bando T, Teraoka H, Sugiyama H. Sequence-specific gene silencing in mammalian cells by alkylating pyrrole-imidazole polyamides. J Am Chem Soc 2004;126:5113-8.
32. Dickinson LA, Burnett R, Melander C, et al. Arresting cancer proliferation by small-molecule gene regulation. Chem Biol 2004;11:1583-94.
33. Tsai SM, Farkas ME, Chou CJ, Gottesfeld JM, Dervan PB. Unanticipated differences between α- and γ-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates. Nucleic Acids Res 2007;35:307-16.
34. Farkas ME, Tsai SM, Dervan PB. α-Diaminobutyric acid-linked hairpin polyamides. Bioorg Med Chem 2007;15:6927-36.
35. Alvarez D, Chou CJ, Latella L, et al. A two-hit mechanism for premitotic arrest of cancer cell proliferation by a polyamide-alkylator conjugate. Cell Cycle 2006;5:1537-48.
36. Baird EE, Dervan PB. Solid phase synthesis of polyamides containing imidazole and pyrrole amino acids. J Am Chem Soc 1996;118:6141-6.
37. Trauger JW, Dervan PB. Footprinting methods for analysis of pyrrole-imidazole polyamide/DNA complexes. Methods Enzymol 2001;340:450-66.
38. Garrity PA, Wold BJ. Effects of different DNA-polymerases in ligation-mediated PCR: enhanced genomic sequencing and in vivo footprinting. Proc Natl Acad Sci U S A 1992;89:1021-5.
39. Sabatino MA, Colombo T, Geroni C, Marchini S, Broggini M. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003;9:5402-8.
40. Shinohara K, Sasaki S, Minoshima M, Bando T, Sugiyama H. Alkylation of template strand of coding region causes effective gene silencing. Nucleic Acids Res 2006;34:1189-95.
41. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
42. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
43. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp Hematol 2001;29:543-56.
44. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
45. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia- chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003;17:829-38.
46. Nimmanapalli R, Bhalla K. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol 2002;14:616-20.